Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2025 16:15 ET | Source: Candel Therapeutics

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, localized prostate cancerRecently announced positive final...
February 26, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Non-Small Cell Lung Cancer Market Set for Significant Growth Across the 7MM During the Study Period (2025-2034) Due to the Rising Novel Therapeutic Options | DelveInsight

New York, USA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Non-Small Cell Lung Cancer Market Set for Significant Growth Across the 7MM During the Study Period (2025-2034) Due to the Rising Novel Therapeutic...
February 10, 2025 08:00 ET | Source: Ocean Biomedical, Inc.

Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) today announced newly...
February 06, 2025 07:00 ET | Source: Immuneering Corporation

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
November 27, 2024 08:00 ET | Source: Immuneering Corporation

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering to Present at the Piper Sandler 36th Annual Healthcare Conference
October 22, 2024 16:01 ET | Source: Genelux Corporation

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent...
August 29, 2024 08:00 ET | Source: Immuneering Corporation

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 06, 2024 16:05 ET | Source: Immuneering Corporation

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
July 31, 2024 16:05 ET | Source: Immuneering Corporation

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
June 01, 2024 10:00 ET | Source: BioNTech SE

Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom

Erste Daten aus einer laufenden Phase-2-Studie zeigten eine 12-Monats-Gesamtüberlebensrate von 69 % und ein medianes Gesamtüberleben von 17,5 Monaten bei Patientinnen und Patienten mit vorbehandeltem,...

Next Page keyboard_arrow_right